TABLE 3 Recommendations by the treating physician regarding adjuvant anti-tumor therapy before (PRE-RS) and after availability (POST-RS) of the Recurrence Score result. For these analyses, patients with recommendations other than CT + HT or HT were excluded.
From: PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Treatment recommendations, n (%) | Change in CT + HT recommendations (%) | |||||
|---|---|---|---|---|---|---|
PRE-RS | POST-RS | |||||
Population | CT + HT | HT | CT + HT | HT | ||
Overall population | N = 1683 | 824 (49%) | 859 (51%) | 524 (31%) | 1159 (69%) | −36% |
N0 | n = 1160 | 512 (44%) | 648 (56%) | 374 (32%) | 786 (68%) | −27% |
Nmic | n = 109 | 54 (50%) | 55 (50%) | 33 (30%) | 76 (70%) | −39% |
N1 | n = 414 | 258 (62%) | 156 (38%) | 110 (28%) | 297 (72%) | −55% |
Grade 3 | n = 475 | 350 (74%) | 125 (26%) | 254 (53%) | 221 (47%) | −27% |
Ki67 > 20% | n = 962 | 608 (63%) | 354 (37%) | 386 (40%) | 576 (60%) | −37% |
Lobular breast cancer | n = 203 | 98 (52%) | 105 48%) | 46 (23%) | 157 (77%) | −53% |
Age > 50 years | n = 1027 | 464 (45%) | 563 (55%) | 314 (31%) | 713 (69%) | −31% |
Age ≤ 50 years | n = 656 | 360 (55%) | 296 (45%) | 210 (32%) | 446 (68%) | −42% |
